Medical Technology Associates, Inc.

mtausa.com

MTA is the largest single-source healthcare compliance company with over three decades of experience. We offer a wide array of Medical Gas Services and Equipment, Environmental Monitoring and Clean Room/Hood Services to healthcare facilities, pharmacies, laboratories and mechanical engineers across the United States and throughout the Caribbean.

Related News

PHARMACYTE BIOTECH ANNOUNCES IND SUBMITTED TO U.S. FDA FOR CLINICAL TRIAL IN LOCALLY ADVANCED, INOPERABLE PANCREATIC CANCER

PharmaCyte Biotech | September 02, 2020

news image

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has submitted an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) for a planned Phase 2b clinical trial in locally advanced, inoperable pancreatic cancer (LAPC). PharmaCyte’s Chief Executive Officer, Kenneth L...

Read More

INDUSTRY OUTLOOK

ANDELYN BIOSCIENCES SELECTS TETRASCIENCE AS A STRATEGIC PARTNER FOR INNOVATION IN THERAPEUTICS DEVELOPMENT AND MANUFACTURING

Andelyn Biosciences | August 26, 2021

news image

TetraScience, the R&D Data Cloud company, announced today that Andelyn Biosciences, Inc. has selected the Tetra Data Platform (TDP) to build a cloud-native development and manufacturing service for its customers. As part of an Andelyn Biosciences initiative to create a Connected Plant that harmonizes data from building and facilities, process and manufacturing, and lab instrument sources, TDP will enable better compliance, easier analysis, faster decisions, and more agile operations. Additio...

Read More

CELL AND GENE THERAPY

SPOTLIGHT THERAPEUTICS CLOSES ITS SERIES A FINANCING BRINGING THE TOTAL RAISED TO $30 MILLION

Spotlight Therapeutics | December 01, 2020

news image

Spotlight Therapeutics, Inc., a biotechnology organization creating non-viral quality altering therapeutics for direct in vivo altering of target genes, closed its Series A financing bringing the complete raised to $30 million. The financing was driven by GV, in the past Google Ventures, with interest from extra undisclosed investors. Realizing the full revolutionary potential of CRISPR genome editing requires the ability to edit target genes directly in the right cells of the hum...

Read More

AXIM® BIOTECHNOLOGIES COMPLETES PRE-CLINICAL DRUG STUDIES ON NEW COMPOUND PROVING TENFOLD GREATER INHIBITION OF TUMOR METASTASIS THAN PARENT COMPOUND

BioSpace | March 24, 2020

news image

Axim Biotech® Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and cannabinoid research, announced today that its subsidiary Sapphire Biotech, Inc. (“Sapphire”) has completed pre-clinical drug studies on a new compound, SPX-1009, demonstrating 10 times greater potency than its parent compound, SBI-183, in inhibiting metastasis....

Read More
news image

PHARMACYTE BIOTECH ANNOUNCES IND SUBMITTED TO U.S. FDA FOR CLINICAL TRIAL IN LOCALLY ADVANCED, INOPERABLE PANCREATIC CANCER

PharmaCyte Biotech | September 02, 2020

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has submitted an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) for a planned Phase 2b clinical trial in locally advanced, inoperable pancreatic cancer (LAPC). PharmaCyte’s Chief Executive Officer, Kenneth L...

Read More
news image

INDUSTRY OUTLOOK

ANDELYN BIOSCIENCES SELECTS TETRASCIENCE AS A STRATEGIC PARTNER FOR INNOVATION IN THERAPEUTICS DEVELOPMENT AND MANUFACTURING

Andelyn Biosciences | August 26, 2021

TetraScience, the R&D Data Cloud company, announced today that Andelyn Biosciences, Inc. has selected the Tetra Data Platform (TDP) to build a cloud-native development and manufacturing service for its customers. As part of an Andelyn Biosciences initiative to create a Connected Plant that harmonizes data from building and facilities, process and manufacturing, and lab instrument sources, TDP will enable better compliance, easier analysis, faster decisions, and more agile operations. Additio...

Read More
news image

CELL AND GENE THERAPY

SPOTLIGHT THERAPEUTICS CLOSES ITS SERIES A FINANCING BRINGING THE TOTAL RAISED TO $30 MILLION

Spotlight Therapeutics | December 01, 2020

Spotlight Therapeutics, Inc., a biotechnology organization creating non-viral quality altering therapeutics for direct in vivo altering of target genes, closed its Series A financing bringing the complete raised to $30 million. The financing was driven by GV, in the past Google Ventures, with interest from extra undisclosed investors. Realizing the full revolutionary potential of CRISPR genome editing requires the ability to edit target genes directly in the right cells of the hum...

Read More
news image

AXIM® BIOTECHNOLOGIES COMPLETES PRE-CLINICAL DRUG STUDIES ON NEW COMPOUND PROVING TENFOLD GREATER INHIBITION OF TUMOR METASTASIS THAN PARENT COMPOUND

BioSpace | March 24, 2020

Axim Biotech® Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and cannabinoid research, announced today that its subsidiary Sapphire Biotech, Inc. (“Sapphire”) has completed pre-clinical drug studies on a new compound, SPX-1009, demonstrating 10 times greater potency than its parent compound, SBI-183, in inhibiting metastasis....

Read More